Bonneville Phoenix Network
 KTAR News
 Arizona Sports
92.3 FM KTAR



Updated Jul 24, 2015 - 6:06 am

AbbVie beats 2Q profit forecasts, but sales fall short

FILE - This Jan. 24, 2015, file photo, shows the exterior of Abbvie, in Lake Bluff, Ill. AbbVie Inc. reports quarterly financial results on Friday, July 24, 2015. (AP Photo/Nam Y. Huh)

NEW YORK (AP) — Drugmaker AbbVie Inc. reported better-than-expected second-quarter profit, but its sales disappointed Wall Street.

The North Chicago, Illinois-based company, which makes the blockbuster anti-inflammatory drug Humira, saw profit rise 24.4 percent to $1.37 billion, or 83 cents per share. Earnings, adjusted for non-recurring costs and amortization costs, came to $1.08 per share.

The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $1.06 per share.

Revenue rose 11.1 percent to $5.48 billion, mainly on a boost in sales of Humira. But, the results fell shy of Wall Street expectations, with five analysts surveyed by Zacks expecting $5.6 billion.

Humira sales rose 7.6 percent to $3.54 billion. The company relies on the drug for the majority of its revenue. It is approved to treat more than a dozen conditions including rheumatoid arthritis, psoriasis and Crohn’s Disease. But, it will start losing patent protection next year and could eventually face competition from Amgen Inc., which is developing a biosimilar version of the drug.

AbbVie’s second-biggest seller, the hepatitis C drug Viekira Pak, was approved in December and brought in $385 million during the second quarter.

Viekira faces a crowded market with already established hepatitis C treatments including Gilead Sciences’ Sovaldi and Harvoni. All three treatments are considered major improvements from earlier drug options.

Looking ahead, AbbVie expects full-year earnings in the range of $4.10 to $4.30 per share.

AbbVie’s stock shed $2.02, or 2.9 percent, hitting $68.50 in premarket trading.

AbbVie shares have risen almost 8 percent since the beginning of the year, while the Standard & Poor’s 500 index has increased 2 percent. The stock has increased 29 percent in the last 12 months.


Elements of this story were generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on ABBV at


Keywords: AbbVie, Earnings Report

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


comments powered by Disqus